Novavax is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants.
technical indicators:
- 88% Barchart technical buy signals
- 187.30+ Weighted Alpha
- Trend Spotter buy signal
- Above its 20, 50 and 100 day moving averages
- 3 new highs and up 8.82% in the last month
- Relative Strength Index 57.04%
- Barchart computes a technical support level at 12.99
- Recently traded at 13.12 with a 50 day moving average of 11.48
- Market Cap $3.52 billion
- Revenue projected to decrease
- Earnings estimated to decrease
- In spite of these projections Wall Street analysts issued 6 strong buy recommendations on the stock
No comments:
Post a Comment